People: Oxford BioMedica PLC (OXB.L)

OXB.L on London Stock Exchange

9.24GBp
31 Jul 2015
Change (% chg)

0.24p (+2.67%)
Prev Close
9.00p
Open
9.49p
Day's High
9.49p
Day's Low
9.00p
Volume
1,246,165
Avg. Vol
4,435,242
52-wk High
13.38p
52-wk Low
2.85p

Search Stocks

Summary

Name Age Since Current Position

Nicholas Rodgers

56 2011 Non-Executive Independent Chairman of the Board

John Dawson

55 2008 Chief Executive Officer, Executive Director

Andrew Heath

66 2011 Non-Executive Deputy Chairman of the Board, Senior Independent Director

Tim Watts

57 2012 Chief Financial Officer, Company Secretary, Executive Director

Paul Blake

66 2014 Executive Director, Chief Development Officer

Peter Nolan

62 2014 Executive Director, Chief Business Officer

Martin Diggle

52 2012 Non-Executive Director

Daniel Soland

56 2015 Non-Executive Director

Biographies

Name Description

Nicholas Rodgers

Mr. Nicholas Rodgers serves as Non-Executive Independent Chairman of the Board of Oxford Biomedica Plc. He was a former investment banker with considerable experience in the life sciences sector. He is currently chairman of SEHTA Enterprises Limited, the commercial arm of South East Health Technologies Alliance and a director of Productiv Limited, an automotive technology enabler. Until January 2013 he was Chief Executive of Ipso Ventures plc having been Head of Life Sciences and joint-Head of Corporate Finance at Evolution Beeson Gregory until December 2003. Mr Rodgers qualified as an accountant with Ernst & Young.

John Dawson

Mr. John Dawson serves as Chief Executive Officer, Executive Director of Oxford BioMedica Plc. From 1996 to 2007, Mr Dawson held senior management positions in the European operations of Cephalon Inc. including, from 2005, a management board position as Chief Financial Officer and Head of Business Development, Europe. In his time at Cephalon he led many of the deals that built the European business to over 1,000 people, taking the business from having no sales in 1998 to revenue of several hundred million US dollars. In 2005, Mr Dawson led the US$360 million acquisition of Zeneus by Cephalon. Between 1991 and 1996 he was Director of Finance and Administration of Serono Laboratories (UK) Limited. Mr Dawson is a non-Executive director of Paion AG.

Andrew Heath

Dr. Andrew J. Heath, M.D., Ph.D., serves as Non-Executive Deputy Chairman of the Board, Senior Independent Director of Oxford BioMedica PLC. Dr Heath is a biopharmaceutical executive with in-depth knowledge of US and UK capital markets and international experience in marketing and sales, R & D and business development. He was Chief Executive Officer of Protherics plc from 1997 to 2008, taking the Company from 30 to 350 staff and managing its eventual acquisition by BTG for £220 million. Prior to this, Dr Heath held senior positions at Astra AB and Astra USA, including Vice President Marketing & Sales, and at Glaxo Sweden as Associate Medical Director.

Tim Watts

Mr. Tim Watts serves as Chief Financial Officer, Company Secretary, Executive Director of Oxford BioMedica PLC. Mr Watts has 25 years experience in the Pharmaceutical and Biotech sectors. From 1 January 2014 he has been a Director of the UK BioIndustry Association. In 1985 he joined ICI, initially in the corporate headquarters and from 1990 in the pharmaceuticals division, eventually becoming Finance Director of the Zeneca Pharmaceuticals business. Following the merger of Astra and Zeneca, Mr Watts became Group Financial Controller of AstraZeneca PLC in 2001. In 2007 he left AstraZeneca to become Chief Financial Officer at Archimedes Pharma. Mr Watts is a member of the Institute of Chartered Accountants in England and Wales.

Paul Blake

Dr. Paul Blake, M.D., is serves as Chief Development Officer, Executive Director of Oxford BioMedica Plc. Dr. Blake has over 30 years international pharmaceutical/biotech experience. From 2006 to 2014 he was Senior Vice President and Chief Medical Officer of Æterna Zentaris Inc., a global biopharmaceutical company focused on oncology and endrocrine therapy. From 2001 to 2006, he held senior management positions at Cephalon Inc, including Executive Vice President, Worldwide Medical & Regulatory Operations from 2005. Dr Blake’s previous positions include Senior Vice President and Medical Director, Clinical Research and Development at SmithKline Beecham Pharmaceuticals. He gained his medical degree from the London University, Royal Free Hospital.

Peter Nolan

Mr. Peter Nolan serves as Chief Business Officer, Executive Director of Oxford Biomedica Plc. Peter Nolan was appointed to the Board in May 2002 having been a senior member of the Group since its foundation and has been the architect of the Group’s IP strategy. His current additional operational responsibilities include Business Development, Contracts/Legal Issues, Quality, Health & Safety and Facilities. Until the end of 2013 he was a Director of the UK BioIndustry Association and he is a past founding Chairman of the Oxfordshire Bioscience Network. Prior to joining Oxford BioMedica, Mr Nolan served as Head of the Biotechnology Unit at the UK Department of Trade and Industry for eight years. In that role he was responsible for establishing and managing complex collaborative research programmes involving industry, research councils and other government departments. Previously he held senior positions in the Laboratory of the Government Chemist and also the Metropolitan Police Laboratory in London where he was a senior forensic scientist.

Martin Diggle

Mr. Martin Diggle serves as Non-Executive Director of Oxford BioMedica PLC. Mr Diggle is a founder of Vulpes Investment Management, a Cayman Fund Manager which currently manages five funds including the Vulpes Life Sciences Fund which is the Group’s second largest shareholder. An investment professional with 30 years experience in investment banking and fund management, Mr Diggle has extensive, first-hand knowledge of the global financial markets and is an expert in emerging markets and Russia, in particular, where he was a partner and director of UBS Brunswick between 1994 and 2003. He has been an investor in life sciences and biotechnology since 1999 and has developed a passionate interest in the sector having worked closely with several companies as a stakeholder over the past decade. Mr Diggle holds a master’s degree in Philosophy, Politics and Economics from University of Oxford, and he is a non-Executive Director of Proteome Sciences plc and Chronos Therapeutics.

Daniel Soland

Mr. Daniel B. Soland is Non-Executive Director of the Company. Mr. Soland was previously Senior Vice President and Chief Operating Officer of ViroPharma from 2008 until its acquisition by Shire in 2014. Prior to this he served as Vice President and Chief Commercial Officer of ViroPharma from 2006 to 2008. During his time at ViroPharma, Mr. Soland managed the commercial, manufacturing and quality organizations, helped build the company's commercial infrastructure in the United States, Europe, and Canada and led the launch of Cinryze®, one of the most successful ultra-orphan drugs in the United States. Prior to this, Mr. Soland was President at Chiron Vaccines from 2005 to 2006. During this time he oversaw the growth of the vaccine business to more than $1 billion in sales. From 2002 through 2005, Mr. Soland served as President and Chief Executive Officer of Epigenesis Pharmaceuticals. Mr. Soland began his career at GlaxoSmithKline in 1993, occupying a number of roles including Vice President and Director, Worldwide Marketing Operations, GSK Biologicals. He currently serves on the board of directors of Tarsa Therapeutics, DBV Technologies SA., and ACADIA Pharmaceuticals.

Basic Compensation

Name Fiscal Year Total

Nicholas Rodgers

75,000

John Dawson

680,000

Andrew Heath

46,000

Tim Watts

425,000

Paul Blake

151,000

Peter Nolan

377,000

Martin Diggle

--

Daniel Soland

--
As Of  30 Dec 2014

Options Compensation

Search Stocks